SCHEMBL5657471

SCHEMBL5657471

COc1cc(F)cc(C2(c3cc(C)c(O)c(C)c3)C(=O)N(c3cccc(C)c3)c3ccccc32)c1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 2/20 0.35
SLC6A2 P23975 1/20 0.33
TP53 P04637 4/20 0.33
MAPT P10636 3/20 0.33
THRB P10828 1/20 0.33
LMNA P02545 3/20 0.32
GAA P10253 3/20 0.32
TSHR P16473 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PGR P06401 1/20 0.32
CACNA1B Q00975 1/20 0.32
APBA1 Q02410 1/20 0.32
HSP90AA1 P07900 1/20 0.32
MGLL Q99685 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658939 0.91 SLC6A2 (0.36) ALDH1A1SLC6A2TP53MAPTTHRB
SCHEMBL5662233 0.84 HSP90AA1 (0.41) ALDH1A1SLC6A2TP53MAPTLMNA
SCHEMBL5660824 0.81 SLC6A2 (0.35) ALDH1A1SLC6A2TP53MAPTTHRB
SCHEMBL5661875 0.81 SLC6A2 (0.37) ALDH1A1KDM4EHPGDSLC6A2TP53
SCHEMBL5659320 0.81 CNR1 (0.37) ALDH1A1SLC6A2TP53MAPTLMNA
SCHEMBL5660585 0.80 PGR (0.46) HSD11B1ALDH1A1SLC6A2TP53MAPT
SCHEMBL5658260 0.80 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDTP53MAPT
SCHEMBL5659702 0.80 NPSR1 (0.37) HSD11B1ALDH1A1KDM4EHPGDSLC6A2
SCHEMBL5656443 0.79 MAPT (0.44) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL5659537 0.79 SLC6A2 (0.36) HSD11B1ALDH1A1KDM4EHPGDSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 HSD11B1 14/4885ALDH1A1 723/4885KDM4E 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.